陣發性睡眠性血尿症治療市場：依治療方法、應用、通路和地區分類

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Therapeutic Approach, By Application, By Distribution Channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年陣發性睡眠性血尿症治療市場規模估計為13.4億美元，預計2033年將達26億美元。預計2026年至2033年，該市場將以11.7%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	13.4億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.70%	2033年市場規模預測：	26億美元

全球陣發性睡眠性血尿症(PNH) 治療市場涵蓋多種治療方法，包括補體抑制劑、基因療法和單株抗體，用於治療與再生障礙性貧血相關的 PNH、經典型 PNH 和無症狀性PNH 等疾病。這些產品已廣泛應用於醫院藥房、零售藥房和線上藥局等各個領域，從而提高了效率、性能和可靠性。這些領域應用範圍的擴大以及持續的產品創新，將繼續推動市場成長。

市場動態：

關鍵應用領域需求的成長、對效率和性能日益重視以及持續的產品創新，預計將成為推動全球陣發性睡眠性血尿症治療市場成長的主要因素。醫院和零售藥局的廣泛應用以及對先進解決方案投資的增加，也進一步促進了市場擴張。

例如，醫療服務提供者正日益開發與再生障礙性貧血相關的陣發性睡眠性血紅蛋白尿症（PNH）及其相關應用的客製化產品和服務。此外，持續的研發投入和新技術的整合預計將在預測期內為市場參與者創造新的成長機會。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司概況、產品系列、主要亮點、財務績效和策略等參數，介紹了全球陣發性睡眠性血尿症治療市場主要參與者的概況。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球陣發性睡眠性血尿症治療市場」報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析陣發性夜間血尿症治療全球市場時所使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 比荷盧經濟聯盟
- 丹麥
- 挪威
- 瑞典
- 其他歐洲國家
亞太地區
- 中國
- 台灣
- 印度
- 日本
- 印尼
- 馬來西亞
- 菲律賓
- 新加坡
- 澳洲
- 韓國
- 其他亞太國家
中東和非洲
巴林
科威特
阿曼
卡達
沙烏地阿拉伯
UAE
以色列
南非
北非
中非
其他中東國家

第1章競爭情勢

Apellis Pharmaceuticals
Alexion Pharmaceuticals（AstraZeneca）
Novartis AG
Roche Holding AG
Alnylam Pharmaceuticals
Sobi（Swedish Orphan Biovitrum）
Sanofi
Biomarin Pharmaceutical Inc.
Rigel Pharmaceuticals
Ikaria Holdings
Hemlibra（Roche）
Ionis Pharmaceuticals

第2章

調查方法
關於本公司

簡介目錄

Product Code: CMI2542

Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market is estimated to be valued at USD 1.34 billion in 2026 and is expected to reach USD 2.6 billion by 2033, growing at a compound annual growth rate (CAGR) of 11.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.34 billion
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.70%	2033 Value Projection:	USD 2.6 billion

The global paroxysmal nocturnal hemoglobinuria therapeutics market comprises therapeutic approach categories such as Complement Inhibitors, Gene Therapy, and Monoclonal Antibodies, serving applications including Aplastic Anemia Associated PNH, Classical PNH, and Subclinical PNH. These offerings are adopted across Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy and other areas, where they support improved efficiency, performance, and reliability. Growing adoption across these segments, combined with ongoing product innovation, continues to support expansion of the market.

Market Dynamics:

Rising demand across key application areas, increasing emphasis on efficiency and performance, and continued product innovation are major factors expected to drive growth of the global paroxysmal nocturnal hemoglobinuria therapeutics market. Expanding adoption among Hospital Pharmacy, and Retail Pharmacy and growing investment in advanced solutions are further supporting market expansion.

For instance, providers are increasingly developing offerings tailored to Aplastic Anemia Associated PNH and related applications. Moreover, ongoing research and development, along with the integration of new technologies, is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global paroxysmal nocturnal hemoglobinuria therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Apellis Pharmaceuticals, Alexion Pharmaceuticals (AstraZeneca), Novartis AG, Roche Holding AG, Alnylam Pharmaceuticals, Sobi (Swedish Orphan Biovitrum), Sanofi, Biomarin Pharmaceutical Inc., Rigel Pharmaceuticals, Ikaria Holdings, Hemlibra (Roche), and Ionis Pharmaceuticals, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global paroxysmal nocturnal hemoglobinuria therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global paroxysmal nocturnal hemoglobinuria therapeutics market.

Detailed Segmentation:

Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Therapeutic Approach (Revenue, USD Bn, 2021 - 2033)
Complement Inhibitors
Gene Therapy
Monoclonal Antibodies
Supportive Care
Others
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Application (Revenue, USD Bn, 2021 - 2033)
Aplastic Anemia Associated PNH
Classical PNH
Subclinical PNH
Others
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Apellis Pharmaceuticals*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Alexion Pharmaceuticals (AstraZeneca)
Novartis AG
Roche Holding AG
Alnylam Pharmaceuticals
Sobi (Swedish Orphan Biovitrum)
Sanofi
Biomarin Pharmaceutical Inc.
Rigel Pharmaceuticals
Ikaria Holdings
Hemlibra (Roche)
Ionis Pharmaceuticals

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapeutic Approach
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Future Prospective
Top Market Players by Revenue

4. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Therapeutic Approach, 2026-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Complement Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Application, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Aplastic Anemia Associated PNH
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Classical PNH
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Subclinical PNH
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Distribution Channel, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market By Region, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, en2026-2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Benelux
  - Denmark
  - Norway
  - Sweden
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - China
  - Taiwan
  - India
  - Japan
  - Indonesia
  - Malaysia
  - Philippines
  - Singapore
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
Bahrain
Kuwait
Oman
Qatar
Saudi Arabia
UAE
Israel
South Africa
North Africa
Central Africa
Rest of the Middle East

1. Competitive Landscape

Apellis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alexion Pharmaceuticals (AstraZeneca)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sobi (Swedish Orphan Biovitrum)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Biomarin Pharmaceutical Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Rigel Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ikaria Holdings
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hemlibra (Roche)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies